The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1677
    
   			ISSUE 1677
May 29, 2023
                			
                		 Issue 1677
                		- Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
 - Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
 - Cariprazine (Vraylar) for Adjunctive Treatment of Depression
 - COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19
 - COVID-19 Update: Metformin to Prevent Long Covid?
 - Polatuzumab vedotin (Polivy) for Lymphoma (online only)
 - Enfortumab Vedotin (Padcev) for Urothelial Cancer (online only)
 - Omidubicel (Omisirge) for Neutrophil Recovery Following Myeloablative Conditioning Therapy (online only)
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
May 29, 2023 (Issue: 1677)
				The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first...more
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				